The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases

Clin Exp Immunol. 2011 May;164(2):145-57. doi: 10.1111/j.1365-2249.2011.04375.x. Epub 2011 Mar 14.

Abstract

Autoimmune diseases are characterized by the body's ability to mount immune attacks on self. This results from recognition of self-proteins and leads to organ damage due to increased production of pathogenic inflammatory molecules and autoantibodies. Over the years, several new potential therapeutic targets have been identified in autoimmune diseases, notable among which are members of the tumour necrosis factor (TNF) superfamily. Here, we review the evidence that certain key members of this superfamily can augment/suppress autoimmune diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Antigens, CD / immunology
  • Autoantigens / immunology
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / immunology
  • Disease Models, Animal
  • Drug Design
  • Drug Evaluation, Preclinical
  • Female
  • Humans
  • Male
  • Mice
  • Mice, Inbred DBA
  • Mice, Inbred NOD
  • Mice, Knockout
  • Receptors, Tumor Necrosis Factor / antagonists & inhibitors*
  • Receptors, Tumor Necrosis Factor / immunology
  • TNF-Related Apoptosis-Inducing Ligand / antagonists & inhibitors
  • TNF-Related Apoptosis-Inducing Ligand / immunology
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • Autoantigens
  • Receptors, Tumor Necrosis Factor
  • TNF-Related Apoptosis-Inducing Ligand
  • Tumor Necrosis Factor-alpha